LATEST MANUSCRIPTS IN ESMO Open
- D J van der Meer, W T A van der Graaf, D van de Wal, H E Karim-Kos, O Husson. Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018. ESMO open. 2024, 9 (1): 102203
Cited : 3Read More - L Incorvaia, G Badalamenti, G Novo, S Gori, L Cortesi, C Brando, S Cinieri, G Curigliano, G R Ricciardi, A Toss, R Chiari, R Berardi, Z Ballatore, M Bono, T D Bazan Russo, V Gristina, A Galvano, G Damerino, L Blasi, V Bazan, A Russo. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). ESMO open. 2023, 9 (1): 102196Cited : 0Read More
- K Liang, J L Feliciano, K A Marrone, J C Murray, C L Hann, V Anagnostou, S A Tackett, E J Shin, R K Hales, K R Voong, R J Battafarano, S C Yang, S R Broderick, J S Ha, P M Forde, J R Brahmer, V K Lam. Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis. ESMO open. 2023, 9 (1): 102199Cited : 0Read More
- J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, G V Scagliotti, M Van den Eynde, S-B Kim, K Kato, L Shen, L Li, N Ding, J Shi, G Barnes, E Van Cutsem. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO open. 2023, 9 (1): 102202Cited : 0Read More
- F Pietrantonio, D Rothwell, S Valpione. Controversies in upper GI: liquid biopsies. ESMO open. 2023, 9 (1): 102204Cited : 0Read More
- S Phadnis, X Wang, N C Daw, C E Herzog, I M Subbiah, W Zaky, M A Gouda, A C Morani, B Amini, D J Harrison, S A Piha-Paul, F Meric-Bernstam, R Gorlick, C L Schwartz, V Subbiah. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO open. 2023, 8 (6): 101609Cited : 0Read More
- Tanja Cufer, Michael P Kosty, . ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. ESMO open. 2023, 8 (6): 101631Cited : 2Read More
- J D Mitchell, M Laurie, Q Xia, B Dreyfus, N Jain, A Jain, D Lane, D J Lenihan. Risk profiles and incidence of cardiovascular events across different cancer types. ESMO open. 2023, 8 (6): 101830Cited : 1Read More
- L Rached, M Frelaut, C Baldini. Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population. ESMO open. 2023, 8 (6): 102029Cited : 3Read More
- L Arecco, E Blondeaux, M Bruzzone, M M Latocca, E Mariamidze, S Begijanashvili, E Sokolovic, G Gentile, G Scavone, S Ottonello, A Boutros, I Vaz-Luis, C Saura, R A Anderson, I Demeestere, H A Azim, E de Azambuja, F A Peccatori, L Del Mastro, A H Partridge, M Lambertini. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis. ESMO open. 2023, 8 (6): 102031Cited : 4Read More
- A Lamarca, V Moreno, V Gambardella, A Cervantes. In the literature: September 2023. ESMO open. 2023, 8 (6): 102032Cited : 0Read More
- J Pearson, A Khan, T Bhogal, H Wong, A Law, S Mills, N Santamaria, J Bishop, J Cliff, D Errington, A Hall, C Hart, Z Malik, R Sripadam, H Innes, H Flint, G Langton, E Ahmed, R Jackson, C Palmieri. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone. ESMO open. 2023, 8 (6): 102033Cited : 3Read More
- Y Tomita, R J Motzer, T K Choueiri, B I Rini, H Miyake, M Oya, L Albiges, M Aizawa, Y Umeyama, J Wang, A di Pietro, M Schmidinger. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO open. 2023, 8 (6): 102034Cited : 2Read More
- C B Westphalen, J Federer-Gsponer, C Pauli, A R Karapetyan, N Chalabi, G Durán-Pacheco, A Beringer, T Bochtler, N Cook, E Höglander, D X Jin, F Losa, L Mileshkin, H Moch, J S Ross, E S Sokol, R W Tothill, A Krämer. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO open. 2023, 8 (6): 102035Cited : 4Read More
- N Brighi, V Conteduca, G Gurioli, E Scarpi, M C Cursano, S Bleve, C Lolli, G Schepisi, C Casadei, C Gianni, P Ulivi, U De Giorgi. Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial. ESMO open. 2023, 8 (6): 102036Cited : 2Read More
